Clopidogrel use in coronary heart disease and percutaneous coronary intervention

Andrew D. Atiemo, Marlene Williams

Research output: Contribution to journalArticle

Abstract

Antiplatelet therapy has proven efficacy in the management of atherothrombosis. Clopidogrel, a thienopyridine, is a potent antiplatelet agent that achieves its antiplatelet effects by inhibiting the binding of adenosine 5' diphos-phate to its platelet receptor. Large clinical trials have demonstrated a role for clopidogrel in the management of symptomatic atherosclerosis, acute coronary syndromes, and patients undergoing percutaneous coronary intervention. In this review, we discuss the pharmacology of clopidogrel including the mechanism of action, review the major clinical trials that have defined the current role of clopidogrel in coronary heart disease and percutaneous coronary intervention, and, finally, examine the concept of clopidogrel resistance and its potential clinical implications.

Original languageEnglish (US)
Pages (from-to)689-700
Number of pages12
JournalJournal of Investigative Medicine
Volume56
Issue number4
StatePublished - Apr 2008

Fingerprint

clopidogrel
Percutaneous Coronary Intervention
Coronary Disease
Clinical Trials
Platelet Aggregation Inhibitors
Acute Coronary Syndrome
Platelets
Adenosine
Atherosclerosis
Blood Platelets
Pharmacology

Keywords

  • CAD
  • Clopidrogel
  • Platelets

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Clopidogrel use in coronary heart disease and percutaneous coronary intervention. / Atiemo, Andrew D.; Williams, Marlene.

In: Journal of Investigative Medicine, Vol. 56, No. 4, 04.2008, p. 689-700.

Research output: Contribution to journalArticle

@article{43d8f46c509e41069f94a76ba857e48c,
title = "Clopidogrel use in coronary heart disease and percutaneous coronary intervention",
abstract = "Antiplatelet therapy has proven efficacy in the management of atherothrombosis. Clopidogrel, a thienopyridine, is a potent antiplatelet agent that achieves its antiplatelet effects by inhibiting the binding of adenosine 5' diphos-phate to its platelet receptor. Large clinical trials have demonstrated a role for clopidogrel in the management of symptomatic atherosclerosis, acute coronary syndromes, and patients undergoing percutaneous coronary intervention. In this review, we discuss the pharmacology of clopidogrel including the mechanism of action, review the major clinical trials that have defined the current role of clopidogrel in coronary heart disease and percutaneous coronary intervention, and, finally, examine the concept of clopidogrel resistance and its potential clinical implications.",
keywords = "CAD, Clopidrogel, Platelets",
author = "Atiemo, {Andrew D.} and Marlene Williams",
year = "2008",
month = "4",
language = "English (US)",
volume = "56",
pages = "689--700",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Clopidogrel use in coronary heart disease and percutaneous coronary intervention

AU - Atiemo, Andrew D.

AU - Williams, Marlene

PY - 2008/4

Y1 - 2008/4

N2 - Antiplatelet therapy has proven efficacy in the management of atherothrombosis. Clopidogrel, a thienopyridine, is a potent antiplatelet agent that achieves its antiplatelet effects by inhibiting the binding of adenosine 5' diphos-phate to its platelet receptor. Large clinical trials have demonstrated a role for clopidogrel in the management of symptomatic atherosclerosis, acute coronary syndromes, and patients undergoing percutaneous coronary intervention. In this review, we discuss the pharmacology of clopidogrel including the mechanism of action, review the major clinical trials that have defined the current role of clopidogrel in coronary heart disease and percutaneous coronary intervention, and, finally, examine the concept of clopidogrel resistance and its potential clinical implications.

AB - Antiplatelet therapy has proven efficacy in the management of atherothrombosis. Clopidogrel, a thienopyridine, is a potent antiplatelet agent that achieves its antiplatelet effects by inhibiting the binding of adenosine 5' diphos-phate to its platelet receptor. Large clinical trials have demonstrated a role for clopidogrel in the management of symptomatic atherosclerosis, acute coronary syndromes, and patients undergoing percutaneous coronary intervention. In this review, we discuss the pharmacology of clopidogrel including the mechanism of action, review the major clinical trials that have defined the current role of clopidogrel in coronary heart disease and percutaneous coronary intervention, and, finally, examine the concept of clopidogrel resistance and its potential clinical implications.

KW - CAD

KW - Clopidrogel

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=58149119719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149119719&partnerID=8YFLogxK

M3 - Article

C2 - 18382265

AN - SCOPUS:58149119719

VL - 56

SP - 689

EP - 700

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 4

ER -